Survival is influenced by approaches to local treatment of Ewing sarcoma within an international randomised controlled trial: analysis of EICESS-92

Table 11 Hazard ratios (CCLG vs. GPOH) according to local treatment modality, among patients with metastatic disease only

	Local treatment modality
	Radiotherapy (RT) alone N = 56	Surgery alone N = 19	RT and surgery N = 66
No. events
EFS	43	11	48
OS	39	8	43
Unadjusted
EFS	0.79 (0.43–1.44)	0.79 (0.24–2.61)	2.01 (0.89–4.54)
OS	0.92 (0.49–1.74)	0.71 (0.18–2.85)	1.98 (0.88–4.47)
Adjusted for age, primary site, histology and time between the start of chemotherapy and starting local treatment
EFS	0.81 (0.44–1.67)	Too few patients to allow for other factors reliably	2.51 (0.89–7.06)
OS	1.01 (0.50–2.01)	Too few patients to allow for other factors reliably	2.54 (0.90–7.20)

Hazard ratios greater than 1 indicate that CCLG patients had a higher risk of having an event or dying compared to GPOH patients
Based on data excluding patients with unknown primary site because there were so few
EFS event-free survival; OS overall survival

ISSN: 2045-3329